why choose us

First received: November 07, 2023

Clinical Trial: An Observational Study to Assess Participant-Reported Real-World Experience of Risankizumab On-body Injector (OBI) for the Treatment of Crohn's Disease in Adult Participants in the United Kingdom (UK)

Study Status: Completed

Recruit Status: RECRUITING

Condition: Crohn's Disease

Study Type: OBSERVATIONAL


Official Title: Patient-reported Real-world Experience of Risankizumab On-body Injector (OBI) for the Treatment of Crohn's Disease in the UK: a Before-and-after Survey of Participants Among Patients That Transit

Brief Summary: Crohn's Disease (CD) is a chronic condition that causes inflammation of the gastrointestinal tract or gut.This study will assess real-world, adult participant experience of self-injection with the risankizumab OBI.Risankizumab is an approved drug for the treatment of CD in adults.Approximately 80 participants who are prescribed risankizumab by their doctors and are transitioning from the pre-filled syringe (PFS) to the use of OBI will be enrolled in this study in the United Kingdom (UK).Participants will…

Read more